Skip to main content
OpenTrials
Completed

NCT Number: NCT02551640

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

The goal of this study is to explore the effects of FeatForward on physical activity and cardio-metabolic risk factors. The study will be implemented as a 2-arm randomized controlled trial (RCT) comparing the effects of FeatForward in patients assigned to use the application versus a control group who will not use the app over a 6-month follow-up period. The investigators hypothesize that subjects using FeatForward will be more physically active and will achieve greater improvements in their cardio-metabolic risk (CMR) factors than a usual care control group that will not use the app over a 6-month period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mass General: Charlestown Healthcare Center, Charlestown, Massachusetts, United States

Loading trial locations.

About this study

TextToMove (TTM) was a dynamic text messaging program which the investigators developed in 2012 with the goals of increasing physical activity in patients with type 2 diabetes mellitus (T2DM), improving self-management of the disease, and lowering HbA1c levels. TTM has since been evaluated in a PHRC-approved randomized controlled trial. In our current proposed study, the investigators plan to convert TTM into a mobile application for smartphone use, with increased and improved functionality and with the potential for easy translation to additional use cases. The investigators used feedback gathered from users and observations from the previous trial to shape the development plan for this second iteration, aptly named "FeatForward." The FeatForward app will be hyper-personalized to users and to respond specifically to individual users' behavior patterns so that the application feels like an intelligent health coach partnering with users to achieve better health outcomes. What defines FeatForward from TTM are additional features, including the incorporation of machine learning components for the messaging algorithm, tailoring of message frequency based on users' activity levels, integration of patient data into the electronic medical records through the Remote Monitoring Data Repository, inputs to improve the generalizability of feedback regarding health metrics (e.g., weight, blood glucose), as well as a community feature to enable interactions with other similar patients and a comprehensive educational library.

FeatForward's primary goal is to help users increase their level of physical activity. Physical inactivity has been identified as one of the leading risk factors contributing to the rising rates of chronic diseases. And despite being the most common cardio-metabolic risk (CMR) factor, it also happens to be the easiest to target. Current estimates suggest that over half (52%) of adults in the United States do not meet the recommended physical activity levels. A number of studies to date have demonstrated the dose-response protective effect of increasing physical activity on the development of diabetes and cardiovascular disease. Therefore, the investigators hypothesize that FeatForward will help users to increase their physical activity levels and also lead to improvements in cardio-metabolic risk factors compared to usual care controls that will not use the intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old
  • Diagnosis of any of the following: pre-diabetes, Type 2 Diabetes Mellitus (T2DM), pre-hypertension, hypertension, and/or obesity (Body Mass Index (BMI) ≥ 30 kg/m2).
  • T2DM: Glycated Hemoglobin (HbA1c) >7.0%
  • Hypertension: Blood Pressure (BP) of 140/90 mmHg
  • Pre-diabetes: HbA1c >5.7% and BMI ≥ 25 kg/m2
  • Pre-hypertension: BP of 130/90 mmHg and family history of high BP
  • Willingness to attend all 3 study visits
  • Ability to read and speak fluent English
  • Physical independence (i.e., ability to walk without assistance)
  • Ability to consent for oneself
  • Willingness to switch to a provided Samsung smartphone and appropriate phone plan to use as a primary phone for the 6-month study duration
  • Willingness to wear a Samsung smartwatch during all hours excluding sleep for the duration of the study

Exclusion criteria

  • Participants with severe depression assessed by scoring ≥20 on the PHQ-8 screening questionnaire for depression
  • Self-reported eating disorder and/or other psychiatric disorders
  • Current or recent participation (within 3 months) in a weight loss program
  • Prior or planned bariatric surgery procedure
  • Use of medications known to cause significant (≥ 5%) long-term changes in body weight or BP
  • Pregnancy or plans to get pregnant within 6 months of enrollment
  • Disability, dementia or neurological deficits, and other medical or surgical conditions preventing participants from engaging in self-care
  • Serious co-morbid conditions (e.g., terminal cancers, end-stage renal disease) that preclude safe participation in moderate levels of physical activity, under discretion of the participants' primary care provider

Treatment and study plan

FeatForward App (on study smartphone)

Other

The FeatForward mobile app will have the following features:

Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.

Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.

Community: Users in later stages of change able to encourage and motivate one another through groups.

Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.

Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.

Social Support: Those using the FeatForward app will also have access to a Facebook group.

Primary outcomes

  1. Differences in the change in physical activity levels between control and intervention groups as measured by daily physical activity measured by the Gear Fit device provided to participants in both groups

    Time frame: 3 & 6 months

Secondary outcomes

  1. Differences in the change in body weight between control and intervention groups

    Time frame: 3 & 6 months

  2. Differences in the change in HbA1c between control and intervention groups

    Time frame: 3 & 6 months

  3. Differences in the change in fasting blood glucose between control and intervention groups

    Time frame: 3 & 6 months

  4. Differences in the change in blood pressure between control and intervention groups

    Time frame: 3 & 6 months

  5. Differences in the change in waist circumference between control and intervention groups

    Time frame: 3 & 6 months

  6. Differences in the change in serum lipids between control and intervention groups

    Time frame: 3 & 6 months

  7. Differences in the change in C-reactive protein between control and intervention groups

    Time frame: 3 & 6 months

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Samsung Electronics

Registry information

Official study title

Improving Physical Activity Behavior in Patients With High Cardio-metabolic Risk Using a Multi-modal mHealth Intervention: a 2-arm Randomized Controlled Trial

Important dates

Study start
2015
Primary completion
2018
Study completion
2019
First posted
Sep 16, 2015
Registry last updated
Sep 1, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.